Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Recruiting
NCT07634471Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Follicular Lymphoma
United States, Argentina, Australia, China, Israel +4 more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +30 more
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)Recruiting
NCT06890884Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Lymphoma, Large B-Cell, Diffuse
United States, Belgium, Germany, Ireland, Israel +4 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting
NCT07216703Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Austria, Belgium, Brazil +23 more
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)Recruiting
NCT06717347Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Diffuse Large B-Cell Lymphoma
United States, Argentina, Australia, Belgium, Brazil +30 more
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive Not Recruiting
NCT03313778Phase 1Updated Sep 3, 2026
Sponsor: ModernaTX, Inc.
Solid Tumors
United States, Australia, Japan, United Kingdom
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)Recruiting
NCT07600749Phase 1Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Canada, Israel, Japan, Switzerland
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)Recruiting
NCT07405151Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Oesophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Czechia +6 more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Recruiting
NCT06393374Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple-Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)Recruiting
NCT07630974Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Belgium, Denmark, France, Israel +3 more
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)Completed
NCT05466422Phase 1Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Alzheimer Disease
United States
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminated
NCT05167409Phase 2Updated Sep 3, 2026
Sponsor: University of Colorado, Denver
Microsatellite Stable Metastatic Colorectal Cancer
United States
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Recruiting
NCT04924075Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Pheochromocytoma/Paraganglioma · Pancreatic Neuroendocrine Tumor · Von Hippel-Lindau Disease · Advanced Gastrointestinal Stromal Tumor
United States, Australia, Canada, Chile, China +17 more
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)Recruiting
NCT06428409Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer
United States, Australia, Canada, Chile, China +8 more
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung CancerAvailable
NCT07535359N/AUpdated Sep 2, 2026
Sponsor: Daiichi Sankyo
SCLC · Extensive-stage Small Cell Lung Cancer
United States
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Recruiting
NCT07286149Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
United States, Brazil, Chile, China, Germany +6 more
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.Recruiting
NCT07365319Phase 2, Phase 3Updated Sep 2, 2026
Sponsor: Eikon Therapeutics
Non Small Cell Lung Cancer (Squamous or Non Squamous) · Stage 4 NSCLC
United States, Australia, Spain
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Recruiting
NCT07252739Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Chile, China, Finland, Greece +8 more
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)Recruiting
NCT07049926Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Renal Cell Carcinoma
United States, Chile, France, Israel, Poland +3 more
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active Not Recruiting
NCT06049212Phase 1Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · Solid Tumors · Programmed Cell Death-1 (PD1, PD-1) · Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Japan
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)Recruiting
NCT06843447Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
United States, Canada, Israel, Spain, United Kingdom
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid TumorsRecruiting
NCT06795412Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Pyxis Oncology, Inc
Advanced Solid Tumors
United States, France, Spain
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Recruiting
NCT06469944Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +7 more
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting
NCT05319730Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Germany +9 more
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Recruiting
NCT07705555Phase 3Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Diabetic Retinopathy · Macular Edema
United States

Previous page Next page